1078P Randomised phase II study of ubamatamab ± cemiplimab in patients (pts) with platinum-resistant ovarian cancer (OC)
June‐Yong Lee, Rebecca C. Arend, S. Bouberhan, Nicoletta Colombo, F. Ghiringhelli, A. González-Martín, F. Joly Lobbedez, Hei Sung Kim, Judith Michels, R.E. O'Cearbhaill, P.B. Ottevanger, K. Papadimitriou, S-Y. Yoo, Bo Wang, Benjamin A. Barnes, J. Brouwer-Visser, Israel Lowy, T.S. Uldrick, E.A. Miller, Els Van Nieuwenhuysen
IF 65.4 (2025) Annals of Oncology
키워드
Ovarian cancerPhases of clinical researchPhase (matter)OvaryAdverse effect